A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy
Read time: 1 mins
Last updated:1st Jul 2010
The primary objective is to assess the treatment effect on progression-free survival (PFS) in patients who receive AUY922 on a once-weekly schedule versus patients who receive docetaxel or irinotecan.
|Study start date||2010-07-01|